C4 Therapeutics, Inc.

NasdaqGS:CCCC Stock Report

Market Cap: US$418.3m

C4 Therapeutics Management

Management criteria checks 4/4

C4 Therapeutics' CEO is Andrew Hirsch, appointed in Sep 2020, has a tenure of 5.92 years. total yearly compensation is $2.94M, comprised of 23.6% salary and 76.4% bonuses, including company stock and options. directly owns 0.11% of the company’s shares, worth $459.70K. The average tenure of the management team and the board of directors is 5.7 years and 8.1 years respectively.

Key information

Andrew Hirsch

Chief executive officer

US$2.9m

Total compensation

CEO salary percentage23.63%
CEO tenure6yrs
CEO ownership0.1%
Management average tenure5.7yrs
Board average tenure8.1yrs

Recent management updates

Recent updates

Seeking Alpha • Sep 05

C4 Therapeutics: Priced For Perfection Ahead Of 2027 Cemsidomide Readouts

Summary C4 Therapeutics is rated Hold, with valuation hinging on the Phase 2 success of its lead asset, cemsidomide. CCCC holds $300.4 million in cash, providing runway through late 2028 and supporting ongoing clinical and partnered programs. The calculated fair value per share is $3.32, below the current $3.71 price, reflecting significant risk if cemsidomide fails. Phase 2 MOMENTUM trial data in late 2027 is the critical catalyst; success could raise fair value to $5.32 per share. Read the full article on Seeking Alpha
Analysis Article • Aug 14

Earnings Beat: C4 Therapeutics, Inc. (NASDAQ:CCCC) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) just released its latest quarterly results and things are looking bullish...
Analysis Article • May 15

C4 Therapeutics, Inc. (NASDAQ:CCCC) Just Reported And Analysts Have Been Lifting Their Price Targets

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) defied analyst predictions to release its quarterly results, which were ahead of...
Analysis Article • Dec 17

Insufficient Growth At C4 Therapeutics, Inc. (NASDAQ:CCCC) Hampers Share Price

You may think that with a price-to-sales (or "P/S") ratio of 7.3x C4 Therapeutics, Inc. ( NASDAQ:CCCC ) is a stock...
Analysis Article • Sep 05

C4 Therapeutics, Inc. (NASDAQ:CCCC) Held Back By Insufficient Growth Even After Shares Climb 33%

Despite an already strong run, C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shares have been powering on, with a gain of 33...
Analysis Article • Jul 11

C4 Therapeutics, Inc. (NASDAQ:CCCC) Surges 27% Yet Its Low P/S Is No Reason For Excitement

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shares have continued their recent momentum with a 27% gain in the last month...
Analysis Article • Jun 20

We Think C4 Therapeutics (NASDAQ:CCCC) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Apr 18

Investors Don't See Light At End Of C4 Therapeutics, Inc.'s (NASDAQ:CCCC) Tunnel And Push Stock Down 40%

Unfortunately for some shareholders, the C4 Therapeutics, Inc. ( NASDAQ:CCCC ) share price has dived 40% in the last...
Seeking Alpha • Mar 10

C4 Therapeutics: Getting Too Cheap To Ignore, But There's Still A Lot Of Risk Here

Summary C4 Therapeutics' pipeline, including cemsidomide and CFT1946, shows early promise but faces significant safety concerns and long timelines for definitive data readouts. Financially, CCCC has sufficient cash to fund operations into 2027, reducing immediate dilution risk, but high cash burn remains a concern. Market valuation has dropped significantly, aligning more closely with their early-stage clinical status, reducing overvaluation risk. Despite potential in protein degraders, the current "Hold" sentiment is maintained due to early-stage data and lack of near-term catalysts. Read the full article on Seeking Alpha
Analysis Article • Mar 04

C4 Therapeutics, Inc. (NASDAQ:CCCC) Looks Inexpensive After Falling 31% But Perhaps Not Attractive Enough

To the annoyance of some shareholders, C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shares are down a considerable 31% in the...
Analysis Article • Nov 15

C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 33% Share Price Plunge Could Signal Some Risk

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shareholders won't be pleased to see that the share price has had a very rough...
Seeking Alpha • Nov 06

C4 Therapeutics: Holding Fast To A Generous Valuation Heading Into An Important ASH Readout

Summary C4 Therapeutics has a promising pipeline, including cemsidomide for blood cancer and CFT1946 for solid tumors, but definitive data is still far off. Financially stable with $59.6M in cash and $196M in marketable securities, CCCC has a cash runway of 11-12 quarters, funding operations through 2025. Strengths include controlled costs and no imminent dilution risk, but the long wait for significant data readouts poses a risk for investors. Maintain a "Hold" rating; worth watching for patient, risk-tolerant investors, but not advisable to jump in headfirst just yet. Read the full article on Seeking Alpha
Analysis Article • Oct 02

We're Not Very Worried About C4 Therapeutics' (NASDAQ:CCCC) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, C4 Therapeutics...
Analysis Article • Aug 09

Analysts' Revenue Estimates For C4 Therapeutics, Inc. (NASDAQ:CCCC) Are Surging Higher

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shareholders will have a reason to smile today, with the analysts making...
Analysis Article • Aug 03

C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 41% Share Price Surge Not Quite Adding Up

Those holding C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shares would be relieved that the share price has rebounded 41% in...
Analysis Article • May 12

Analysts Just Published A Bright New Outlook For C4 Therapeutics, Inc.'s (NASDAQ:CCCC)

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shareholders will have a reason to smile today, with the analysts making...
Seeking Alpha • Mar 01

C4 Therapeutics' TORPEDO Platform Is Promising, But Its Valuation Remains Stretched

Summary C4 Therapeutics is developing targeted protein degraders for the treatment of various diseases, including cancer. The company's TORPEDO platform allows for the design of molecules that can break down disease-causing proteins. C4 Therapeutics has a partnership with Merck and is currently in Phase 1 clinical trials for its drug candidates. The company's current valuation appears high compared to sector peers, leading to a "hold" rating. Read the full article on Seeking Alpha
Analysis Article • Feb 29

Party Time: Brokers Just Made Major Increases To Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Earnings Forecasts

Shareholders in C4 Therapeutics, Inc. ( NASDAQ:CCCC ) may be thrilled to learn that the analysts have just delivered a...
Analysis Article • Feb 24

C4 Therapeutics, Inc. (NASDAQ:CCCC) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

It's been a pretty great week for C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shareholders, with its shares surging 13% to...
Analysis Article • Nov 03

New Forecasts: Here's What Analysts Think The Future Holds For C4 Therapeutics, Inc. (NASDAQ:CCCC)

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shareholders will have a reason to smile today, with the analysts making...

CEO Compensation Analysis

How has Andrew Hirsch's remuneration changed compared to C4 Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2026n/an/a

-US$101m

Mar 31 2026n/an/a

-US$104m

Dec 31 2025US$3mUS$695k

-US$105m

Sep 30 2025n/an/a

-US$119m

Jun 30 2025n/an/a

-US$112m

Mar 31 2025n/an/a

-US$103m

Dec 31 2024US$5mUS$665k

-US$105m

Sep 30 2024n/an/a

-US$105m

Jun 30 2024n/an/a

-US$108m

Mar 31 2024n/an/a

-US$126m

Dec 31 2023US$4mUS$639k

-US$132m

Sep 30 2023n/an/a

-US$135m

Jun 30 2023n/an/a

-US$140m

Mar 31 2023n/an/a

-US$131m

Dec 31 2022US$3mUS$614k

-US$128m

Sep 30 2022n/an/a

-US$107m

Jun 30 2022n/an/a

-US$99m

Mar 31 2022n/an/a

-US$95m

Dec 31 2021US$952kUS$580k

-US$84m

Sep 30 2021n/an/a

-US$80m

Jun 30 2021n/an/a

-US$82m

Mar 31 2021n/an/a

-US$73m

Dec 31 2020US$21mUS$168k

-US$66m

Compensation vs Market: Andrew's total compensation ($USD2.94M) is about average for companies of similar size in the US market ($USD2.41M).

Compensation vs Earnings: Andrew's compensation has been consistent with company performance over the past year.

CEO

Andrew Hirsch (55 yo)

6yrs
Tenure
US$2,940,975
Compensation

Mr. Andrew J. Hirsch, M.B.A., is Independent Director of Akamis Bio Limited from August 2025. He is the President of C4 Therapeutics, Inc since September 14, 2020 and has been its Chief Executive Officer s...

Leadership Team

NamePositionTenureCompensationOwnership
Andrew Hirsch
CEO, President & Director6yrsUS$2.94m0.11%
$ 459.7k
Kenneth Anderson
Co-Founderno dataUS$85.50k0.29%
$ 1.2m
Kendra Adams
Principal Accounting Officer3yrsUS$1.48m0.037%
$ 153.6k
Leonard M. Reyno
Chief Medical Officer3.2yrsUS$1.64m0.027%
$ 113.6k
Nathanael Gray
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Courtney Solberg
Senior Manager of Investor Relationsno datano datano data
Kelly Schick
Chief People Officer5.7yrsno data0.032%
$ 132.1k
Isabel Chiu
Senior Vice President of Strategic Alliances & Business Development10.5yrsno datano data
Christopher Nasveschuk
Senior Vice President of Chemistry5.7yrsno datano data
Roy Pollock
Senior Vice President of Biological Sciences7.6yrsno datano data
Mayra Reyes-Armour
Senior Vice President of Technical Operations5.7yrsno datano data
Scott Boyle
Chief Business Officer4.7yrsUS$3.91m0.031%
$ 128.5k
5.7yrs
Average Tenure
52yo
Average Age

Experienced Management: CCCC's management team is seasoned and experienced (5.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Andrew Hirsch
CEO, President & Director5.9yrsUS$2.94m0.11%
$ 459.7k
Kenneth Anderson
Co-Founder10.8yrsUS$85.50k0.29%
$ 1.2m
Nathanael Gray
Co-Founder & Member of Scientific Advisory Board9.8yrsno datano data
Christopher Bowden
Member of Clinical Advisory Boardno datano datano data
Steven Hoerter
Independent Director1.8yrsUS$90.31kno data
Christopher Kirk
Member of Scientific Advisory Board9.8yrsno datano data
Ross Levine
Member of Scientific Advisory Board9.2yrsno datano data
Ronald H. Cooper
Independent Chairman2.3yrsUS$119.25k0%
$ 0
Ryan Corcoran
Member of Scientific Advisory Board7yrsno datano data
Scott Armstrong
Member of Scientific Advisory Board9.2yrsno datano data
Utpal Koppikar
Independent Director4.5yrsUS$100.50k0.0046%
$ 19.3k
Beni Wolf
Member of Clinical Advisory Boardno datano datano data
8.1yrs
Average Tenure
55yo
Average Age

Experienced Board: CCCC's board of directors are considered experienced (8.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/11 07:39
End of Day Share Price 2026/09/11 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

C4 Therapeutics, Inc. is covered by 14 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Etzer DaroutBarclays
Chi Meng FongBofA Global Research
Leah Rush CannBrookline Capital Markets